All In Biotech

Drug Trial Radar · NCT02487069

Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy

Allogeneic Stem Cell Transplantation With Alternative Donor in Treatment of Hematologic Malignancy

Last checked: Nov 20, 2026Latest source record: Mar 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

876

Actual

Start

Jun 2015

Primary completion

Jan 31, 2020

Study completion Feb 29, 2020

Sponsor

Lead sponsor
Nanfang Hospital, Southern Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Guangdong Provincial People's Hospital; Third Affiliated Hospital, Sun Yat-Sen University; Guangzhou General Hospital of Guangzhou Military Command; Guangzhou First People's Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Zhujiang Hospital; Tongji Hospital; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Fujian Medical University Union Hospital; First Affiliated Hospital of Guangxi Medical University; Xiangya Hospital of Central South University
First posted
Jul 1, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) from matched sibling donor (MSD),matched unrelated donor (MUD) and haploidentical related donors(HRD) in the treatment of hematologic malignancy.

Conditions

  • Acute Leukemia
  • Chronic Myeloid Leukemia
  • Myelodysplastic Syndrome

Interventions

  • HSCT from MSDProcedure

    HSCT from MSD is the first choice for the patients who have HLA-matched sibling donors.

  • HSCT from MUDProcedure

    HSCT from MUD is the second choice for the patients who don't have HLA-matched sibling donors but have HLA-matched unrelated donors.

  • HSCT from HRDProcedure

    HSCT from HRD is the choice for the patients who have neither HLA-matched sibling donors nor HLA-matched unrelated donors.

  • Cyclosporin ADrug

    CsA is used in all the patients for GVHD prophylaxis.

  • MethotrexateDrug

    MTX is used in all the patients for GVHD prophylaxis.

  • Antithymocyte globulinDrug

    ATG is used in the patients receiving HSCT from MUD and HRD for GVHD prophylaxis.In MUD group,total ATG doses is 7 mg/kg;In HRD group,total ATG doses is 7.5 or 10 mg/kg.

  • Mycophenolate mofetilDrug

    MMF is used in the patients receiving HSCT from MSD and HRD for GVHD prophylaxis.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: 3 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Hematology,Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.